Corticosteroids in Cardiogenic Shock: A Retrospective Analysis of the Medical Information Mart for Intensive Care-IV Database.

Q4 Medicine Critical care explorations Pub Date : 2025-01-31 eCollection Date: 2025-02-01 DOI:10.1097/CCE.0000000000001210
Ghazal Haddad, David M Maslove, Lawrence Mbuagbaw, Emilie P Belley-Côté, Bram Rochwerg
{"title":"Corticosteroids in Cardiogenic Shock: A Retrospective Analysis of the Medical Information Mart for Intensive Care-IV Database.","authors":"Ghazal Haddad, David M Maslove, Lawrence Mbuagbaw, Emilie P Belley-Côté, Bram Rochwerg","doi":"10.1097/CCE.0000000000001210","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>While corticosteroid administration in septic shock has been shown to result in faster shock reversal and lower short-term mortality, the role of corticosteroids in the management of cardiogenic shock (CS) remains unexplored.</p><p><strong>Objectives: </strong>Determine the impact of corticosteroid administration on 90-day mortality (primary outcome) in patients admitted to a critical care unit with CS.</p><p><strong>Design, setting, and participants: </strong>In this retrospective cohort study, we used the critical care database of Medical Information Mart for Intensive Care-IV, and included all adult patients diagnosed with CS excluding repeated admissions, patients with adrenal insufficiency, those receiving baseline corticosteroids, and those requiring extracorporeal life support. We considered exposure based on receiving systemic corticosteroids from 6 hours before to 24 hours post-critical care admission.</p><p><strong>Main outcomes and measures: </strong>We calculated Cox proportional hazards using multivariate analysis for 90-day mortality (primary outcome). We also explored the association of corticosteroid use with hospital length of stay, ventilator-free days (VFDs), vasopressor-free days, ventilator-associated pneumonia, central-line-associated bloodstream infections, and hyperglycemia.</p><p><strong>Results: </strong>We included 2000 eligible patients, with 143 (7.2%) receiving systemic corticosteroids. Corticosteroid-treated patients were younger (67.7 vs. 71.2 yr; p = 0.006), had higher Sequential Organ Failure Assessment scores at baseline (9.4 vs. 7.8; p < 0.001), and more often required vasopressors (78% vs. 63%; p < 0.001), and invasive mechanical ventilation (73% vs. 45%; p < 0.001). Corticosteroid use was associated with increased 90-day mortality in multivariate analysis (hazard ratio, 1.60; 95% CI, 1.25-2.05) and fewer VFDs (2.8 d fewer; 95% CI, 0.35-5.26) with no effect on other secondary outcomes.</p><p><strong>Conclusions and relevance: </strong>Use of corticosteroids may be associated with increased mortality and a reduction in VFDs in patients admitted to critical care with CS. These findings suggesting potential harm of corticosteroids in CS might reflect unmeasured confounding and require corroboration through additional observational studies and ultimately randomized clinical trials.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":"7 2","pages":"e1210"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789865/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical care explorations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CCE.0000000000001210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: While corticosteroid administration in septic shock has been shown to result in faster shock reversal and lower short-term mortality, the role of corticosteroids in the management of cardiogenic shock (CS) remains unexplored.

Objectives: Determine the impact of corticosteroid administration on 90-day mortality (primary outcome) in patients admitted to a critical care unit with CS.

Design, setting, and participants: In this retrospective cohort study, we used the critical care database of Medical Information Mart for Intensive Care-IV, and included all adult patients diagnosed with CS excluding repeated admissions, patients with adrenal insufficiency, those receiving baseline corticosteroids, and those requiring extracorporeal life support. We considered exposure based on receiving systemic corticosteroids from 6 hours before to 24 hours post-critical care admission.

Main outcomes and measures: We calculated Cox proportional hazards using multivariate analysis for 90-day mortality (primary outcome). We also explored the association of corticosteroid use with hospital length of stay, ventilator-free days (VFDs), vasopressor-free days, ventilator-associated pneumonia, central-line-associated bloodstream infections, and hyperglycemia.

Results: We included 2000 eligible patients, with 143 (7.2%) receiving systemic corticosteroids. Corticosteroid-treated patients were younger (67.7 vs. 71.2 yr; p = 0.006), had higher Sequential Organ Failure Assessment scores at baseline (9.4 vs. 7.8; p < 0.001), and more often required vasopressors (78% vs. 63%; p < 0.001), and invasive mechanical ventilation (73% vs. 45%; p < 0.001). Corticosteroid use was associated with increased 90-day mortality in multivariate analysis (hazard ratio, 1.60; 95% CI, 1.25-2.05) and fewer VFDs (2.8 d fewer; 95% CI, 0.35-5.26) with no effect on other secondary outcomes.

Conclusions and relevance: Use of corticosteroids may be associated with increased mortality and a reduction in VFDs in patients admitted to critical care with CS. These findings suggesting potential harm of corticosteroids in CS might reflect unmeasured confounding and require corroboration through additional observational studies and ultimately randomized clinical trials.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
重要性:虽然在脓毒性休克中使用皮质类固醇可加快休克逆转并降低短期死亡率,但皮质类固醇在心源性休克(CS)治疗中的作用仍有待探索:确定使用皮质类固醇对入住重症监护病房的心源性休克患者 90 天死亡率(主要结果)的影响:在这项回顾性队列研究中,我们使用了重症监护医学信息中心(Medical Information Mart for Intensive Care-IV)的重症监护数据库,纳入了所有确诊为 CS 的成年患者,但不包括重复入院患者、肾上腺功能不全患者、接受基础皮质类固醇治疗的患者以及需要体外生命支持的患者。我们根据患者入院前6小时至入院后24小时内接受过全身性皮质类固醇治疗的情况来考虑其暴露情况:我们通过多变量分析计算了 90 天死亡率(主要结果)的 Cox 比例危险度。我们还探讨了皮质类固醇的使用与住院时间、无呼吸机天数(VFDs)、无血管舒张剂天数、呼吸机相关肺炎、中央管路相关血流感染和高血糖的关系:我们纳入了 2000 名符合条件的患者,其中 143 人(7.2%)接受了全身皮质类固醇治疗。接受皮质类固醇治疗的患者更年轻(67.7 岁对 71.2 岁;p = 0.006),基线时的序贯器官衰竭评估评分更高(9.4 分对 7.8 分;p < 0.001),更经常需要使用血管加压药(78% 对 63%;p < 0.001)和有创机械通气(73% 对 45%;p < 0.001)。在多变量分析中,使用皮质类固醇与 90 天死亡率增加(危险比为 1.60;95% CI,1.25-2.05)和 VFD 减少(减少 2.8 天;95% CI,0.35-5.26)有关,但对其他次要结果没有影响:使用皮质类固醇可能与CS危重症患者死亡率增加和VFD减少有关。这些研究结果表明皮质类固醇对 CS 有潜在危害,可能反映了未测量的混杂因素,需要通过更多的观察性研究和最终的随机临床试验来证实。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
0
审稿时长
8 weeks
期刊最新文献
The Maastricht Intensive Care COVID Cohort: A Critical Appraisal of the Predefined Research Questions. Corticosteroids in Cardiogenic Shock: A Retrospective Analysis of the Medical Information Mart for Intensive Care-IV Database. Proteomic Analyses in COVID-19-Associated Secondary Hemophagocytic Lymphohistiocytosis. The Diagnostic Utility of Host RNA Biosignatures in Adult Patients With Sepsis: A Systematic Review and Meta-Analysis. Heterogeneity of Intermediate Care Organization Within a Single Healthcare System.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1